A generic drug used to treat malaria may be as
promising as any that companies are currently scrambling for to treat
COVID-19, the coronavirus-related disease spreading rapidly, Raymond
James says.
Analyst Steven Seedhouse says chloroquine – a
longtime oral anti-malarial that costs pennies per dose – could turn out
“more effective, scalable, and affordable” than the candidates being
studied by companies including AbbVie (NYSE:ABBV), Gilead (NASDAQ:GILD), and Regeneron (NASDAQ:REGN), not to mention Moderna (NASDAQ:MRNA), GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and others.
After very early indications of efficacy in China,
chloroquine is seeing increased demand suggesting it may be seeing
real-world use already, though ultimate efficacy depends on data that
still need to be gathered.
https://seekingalpha.com/news/3550389-generic-anti-malarial-may-treat-covidminus-19-raymond-james
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.